Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity
Introduction/Objective. Primary open-angle glaucoma (POAG) treatment should be individually tailored to the disease severity and type, effectiveness and secondary side effects of the medications used. This research aimed to assess the direct medical costs and the cost effectiveness associated with p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Serbian Medical Society
2022-01-01
|
| Series: | Srpski Arhiv za Celokupno Lekarstvo |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200021V.pdf |
| _version_ | 1811288845377863680 |
|---|---|
| author | Velkovski Zoran Belevska Maja Gjorgjeska Biljana Đorđević-Jocić Jasmina |
| author_facet | Velkovski Zoran Belevska Maja Gjorgjeska Biljana Đorđević-Jocić Jasmina |
| author_sort | Velkovski Zoran |
| collection | DOAJ |
| description | Introduction/Objective. Primary open-angle glaucoma (POAG) treatment should be individually tailored to the disease severity and type, effectiveness and secondary side effects of the medications used. This research aimed to assess the direct medical costs and the cost effectiveness associated with pharmacotherapy in visually impaired people with POAG according to disease severity. Methods. This scientific study is designed as an observational cross-sectional study with a quantitative analytical approach and was conducted in the period from July 2020 to June 2021 on the territory of North Macedonia. The study included 157 patients with binocular POAG in the early, moderate and advanced clinical stage, up to the age of 67, with changes in visual acuity and work ability. During the assessment of the effects of pharmacotherapy were analyzed the types, mutual correlations and effectiveness of the most commonly prescribed antiglaucomatous medications and the cost benefit from their administration. Direct medical costs are calculated according to disease severity in the last 12 months using real-time data of public interest. Results. The beta blockers due to their affordable price and availability are the dominant option with high-cost benefit for primary treatment of POAG. Antiglaucoma medications and diagnostic procedures are major components of direct medical treatment costs. Conclusion. Pharmacotherapy is the dominant alternative compared to other types of treatment because it is safer and is associated with greater effectiveness and lower direct medical costs. |
| first_indexed | 2024-04-13T03:44:27Z |
| format | Article |
| id | doaj.art-3ffe2c7215d34c9084adde0aa6571c4d |
| institution | Directory Open Access Journal |
| issn | 0370-8179 2406-0895 |
| language | English |
| last_indexed | 2024-04-13T03:44:27Z |
| publishDate | 2022-01-01 |
| publisher | Serbian Medical Society |
| record_format | Article |
| series | Srpski Arhiv za Celokupno Lekarstvo |
| spelling | doaj.art-3ffe2c7215d34c9084adde0aa6571c4d2022-12-22T03:04:03ZengSerbian Medical SocietySrpski Arhiv za Celokupno Lekarstvo0370-81792406-08952022-01-011503-417718210.2298/SARH211219021V0370-81792200021VCost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severityVelkovski Zoran0Belevska Maja1Gjorgjeska Biljana2Đorđević-Jocić Jasmina3Medical University Sofia, Faculty of Pharmacy, Sofia, BulgariaSt Kliment Ohridski Bitola University, Clinical Hospital Bitola, Bitola, North MacedoniaGoce Delchev Shtip University, Faculty of Medical Sciences, Štip, North MacedoniaUniversity of Niš, Faculty of Medicine, Clinic of Ophthalmology, Niš, SerbiaIntroduction/Objective. Primary open-angle glaucoma (POAG) treatment should be individually tailored to the disease severity and type, effectiveness and secondary side effects of the medications used. This research aimed to assess the direct medical costs and the cost effectiveness associated with pharmacotherapy in visually impaired people with POAG according to disease severity. Methods. This scientific study is designed as an observational cross-sectional study with a quantitative analytical approach and was conducted in the period from July 2020 to June 2021 on the territory of North Macedonia. The study included 157 patients with binocular POAG in the early, moderate and advanced clinical stage, up to the age of 67, with changes in visual acuity and work ability. During the assessment of the effects of pharmacotherapy were analyzed the types, mutual correlations and effectiveness of the most commonly prescribed antiglaucomatous medications and the cost benefit from their administration. Direct medical costs are calculated according to disease severity in the last 12 months using real-time data of public interest. Results. The beta blockers due to their affordable price and availability are the dominant option with high-cost benefit for primary treatment of POAG. Antiglaucoma medications and diagnostic procedures are major components of direct medical treatment costs. Conclusion. Pharmacotherapy is the dominant alternative compared to other types of treatment because it is safer and is associated with greater effectiveness and lower direct medical costs.http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200021V.pdfpharmacotherapydirect medical costsantiglaucoma medicationseconomic burden |
| spellingShingle | Velkovski Zoran Belevska Maja Gjorgjeska Biljana Đorđević-Jocić Jasmina Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity Srpski Arhiv za Celokupno Lekarstvo pharmacotherapy direct medical costs antiglaucoma medications economic burden |
| title | Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity |
| title_full | Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity |
| title_fullStr | Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity |
| title_full_unstemmed | Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity |
| title_short | Cost effectiveness analysis associated to the treatment of primary open-angle glaucoma according to disease severity |
| title_sort | cost effectiveness analysis associated to the treatment of primary open angle glaucoma according to disease severity |
| topic | pharmacotherapy direct medical costs antiglaucoma medications economic burden |
| url | http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200021V.pdf |
| work_keys_str_mv | AT velkovskizoran costeffectivenessanalysisassociatedtothetreatmentofprimaryopenangleglaucomaaccordingtodiseaseseverity AT belevskamaja costeffectivenessanalysisassociatedtothetreatmentofprimaryopenangleglaucomaaccordingtodiseaseseverity AT gjorgjeskabiljana costeffectivenessanalysisassociatedtothetreatmentofprimaryopenangleglaucomaaccordingtodiseaseseverity AT đorđevicjocicjasmina costeffectivenessanalysisassociatedtothetreatmentofprimaryopenangleglaucomaaccordingtodiseaseseverity |